Pharma purchase: Colcrys to Takeda
Steve’s breakdown: Key line of this article: “Takeda America will immediately assume the marketing and promotion of Colcrys” And with sales of about $430 million in 2011, they’ll have an advertising budget in the 7 to 8 figures. And check out their print!!
DEERFIELD, IL & PHILADELPHIA, PA: Takeda Pharmaceutical Co. Ltd., completed its $800 million cash purchase of URL Pharma, Inc., and the acquisition will immediately add $550 million in sales this year, the company said Monday.
Deerfield-based Takeda America will immediately assume the marketing and promotion of Colcrys, a treatment for gout and URL Pharma’s leading product. Takeda’s Deerfield-based subsidiary already has another product, Uloric, that works to prevent gout attacks.
URL Pharma, based in Philadelphia, will be managed by Takeda Pharmaceuticals U.S.A., and its present, Douglas Cole. When the deal was announced in April, Cole said the primary goal of the acquisition was to gain Colcrys “so we can be the only company that treats both acute and chronic gout.
Net sales for Colcrys in 2011 were more than $430 million.
The acquisition also includes the possibility of future payments, dependent of the company’s performance.